• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [23156 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2023     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Health technology assessment framework: adaptation for digital health technology assessment]
2023     Health Technology Wales (HTW) Solution-focused assessment tools for improving the treatment of people with psychosis and schizophrenia within secondary mental health services
2023     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Peripheral electrical nerve stimulation (PENS) therapy as treatment for refractory chronic neuropathic pain in adults: evaluation of safety, efficacy, clinical effectiveness, and cost-effectiveness]
2023     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Remote monitoring of lung function through self-administered spirometry in patients with asthma, chronic obstructive pulmonary disease or cystic fibrosis: evaluation of safety, clinical efficacy and implementation aspects]
2023     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [PCR type nucleic acid amplification tests in blood applied to rapid etiological diagnosis in suspected sepsis: assessment of its diagnostic and prognostic utility, safety, and economic and organizational implementation considerations]
2023     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Safety, efficacy, and economic evaluation of the implementation of an abdominal aortic aneurysm screening program]
2023     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Blood test for the identification and location of different types of cancer]
2023     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Artificial intelligence for the detection of colorectal precancerous lesions in colonoscopy]
2023     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of early intervention programs in psychosis for adolescents and young adults]
2023     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of the safety, diagnostic validity, and clinical effectiveness of transcutaneous measurement of partial pressure of oxygen in the management of diabetic foot]
2023     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Spinal cord stimulation in refractory neuropathic pain in adults: evaluation of efficacy, effectiveness, safety, and efficiency in painful diabetic neuropathy and failed back surgery and complex regional pain syndromes]
2023     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Robotic surgery in benign and malignant surgical pathology (urology, general and digestive surgery, cardiothoracic surgery, gynecology, endocrinology, ophthalmology, and head and neck surgery). Chapter II: urological, gynecological, general and digestive surgery]
2023     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Robotic surgery in benign and malignant surgical pathology (urology, general and digestive surgery, cardiothoracic surgery, gynecology, endocrinology, ophthalmology, and head and neck surgery). Chapter I: cardiothoracic, endocrine, ophthalmological surgery, and head and neck surgery]
2023     Health Technology Wales (HTW) Percutaneous implantation of pulmonary artery pressure sensors for monitoring treatment of chronic heart failure
2023     Austrian Institute for Health Technology Assessment (AIHTA) [Endovenous laser therapy for varicose veins in the lower extremities]
2023     Austrian Institute for Health Technology Assessment (AIHTA) [Autologous fat grafting in osteoarthritis]
2023     Austrian Institute for Health Technology Assessment (AIHTA) [Registries in Austria and their utilisation for healthcare improvement]
2023     Austrian Institute for Health Technology Assessment (AIHTA) [Myopia control spectacle lenses for children and adolescents]
2023     Austrian Institute for Health Technology Assessment (AIHTA) [Strategies for recruitment and programme adherence in group programmes for children, adolescents and adults with overweight and grade 1 obesity]
2023     Austrian Institute for Health Technology Assessment (AIHTA) SMA therapies: mid- to long-term follow-up of spinal muscular atrophy (SMA) patients treated for ≥24 months with nusinersen or onasemnogene abeparvovec and ≥12 months for patients treated with risdiplam or combination therapies
2023     Austrian Institute for Health Technology Assessment (AIHTA) [Robot-assisted rehabilitation for incomplete spinal cord injury]
2023     Austrian Institute for Health Technology Assessment (AIHTA) Image-guided spinal injections in the treatment of chronic spinal pain: an overview of evidence-based guideline recommendations and specific focus on guidance techniques
2023     NIHR Health Technology Assessment programme Techniques to increase lumbar puncture success in newborn babies: the NeoCLEAR RCT
2023     NIHR Health Technology Assessment programme Treatment of Hidradenitis Suppurativa Evaluation Study: the THESEUS prospective cohort study
2023     NIHR Health Technology Assessment programme Ablative and non-surgical therapies for early and very early hepatocellular carcinoma: a systematic review and network meta-analysis
2023     NIHR Health Services and Delivery Research programme Evaluating mental health decision units in acute care pathways (DECISION): a quasi-experimental, qualitative and health economic evaluation
2023     NIHR Health Technology Assessment programme The potential impact of policies and structural interventions in reducing cardiovascular disease and mortality: a systematic review of simulation-based studies
2023     NIHR Health Services and Delivery Research programme The effectiveness and acceptability of multimedia information when recruiting children and young people to trials: the TRECA meta-analysis of SWATs
2023     NIHR Health Services and Delivery Research programme Impact of interventions to improve recovery of older adults following planned hospital admission on quality-of-life following discharge: linked-evidence synthesis
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: assessment of Intercept and Mirasol - pathogen reduction technologies for the treatment of labile blood products in Quebec]
2023     Scottish Health Technologies Group (SHTG) Digital prevention programme for people at risk of type 2 diabetes
2023     Scottish Health Technologies Group (SHTG) Technology-enabled theatre scheduling systems
2023     Scottish Health Technologies Group (SHTG) Capsule sponge technologies for the detection of Barrett’s oesophagus and early stage oesophageal cancer
2023     Scottish Health Technologies Group (SHTG) The cost-effectiveness of the Scottish Hip Fracture Audit
2023     Scottish Health Technologies Group (SHTG) Priorities for the north imaging alliance
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: principles and criteria guiding the use of parent-child trio genomewide sequencing in constitutional genetics - a report to support the work of the RQDM]
2023     Malaysian Health Technology Assessment (MaHTAS) Negative pressure wound therapy
2023     Malaysian Health Technology Assessment (MaHTAS) Human skin allograft for burns
2023     Malaysian Health Technology Assessment (MaHTAS) Nasojejunal tube in upper gastrointestinal conditions
2023     Malaysian Health Technology Assessment (MaHTAS) Bio-electrical impedance analysis for the assessment of sarcopenia in elderly
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on diagnosis and treatment of gout: lifestyle changes for gout]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on diagnosis and treatment of gout: treatment of comorbidities]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on diagnosis and treatment of gout: allopurinol versus febuxostat]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on diagnosis and treatment of gout: xanthine oxidase inhibitors]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on diagnosis and treatment of gout: drug treatment of a gout attack]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on diagnosis and treatment of gout: test accuracy of various methods for diagnosing gout]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on oropharyngeal dysphagia due to head and neck tumours – diagnosis and treatment: tumour resection]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on oropharyngeal dysphagia due to head and neck tumours – diagnosis and treatment: Intensity-modulated radiotherapy under consideration of swallowing function]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on oropharyngeal dysphagia due to head and neck tumours – diagnosis and treatment: Prophylactic percutaneous endoscopic gastrostomy tube]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on oropharyngeal dysphagia due to head and neck tumours – diagnosis and treatment: Self-evaluation of swallowing behaviour]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on oropharyngeal dysphagia due to head and neck tumours – diagnosis and treatment: Triage tests in the context of dysphagia diagnostics]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Loncastuximab tesirine (DLBCL and HGBL) – Addendum to Commission A23-45]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tisagenlecleucel (ALL) – Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dalbavancin (acute bacterial infections of the skin and the soft tissue, = 3 months) - Assessment according to § 35a (1c), Social Code Book (SGB) V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Bedaquiline (tuberculosis) – Assessment according to § 35a (1), Sentence 11, Social Code Book (SGB) V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Glofitamab (diffuse large B-cell lymphoma) – Assessment according to § 35a Social Code Book (SGB) V (1) Sentence 11]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sacubitril/valsartan (heart failure, children and adolescents) – Addendum to Commission A23-56]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lisocabtagene maraleucel (DLBCL, HGBL, PMBCL and FL3B, second line) – Addendum to Commission A23-48]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tixagevimab/cilgavimab (pre-exposure prophylaxis of COVID-19) – Addendum to Commission A23-42]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vosoritide (achondroplasia, ≥ 2 years) – Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Teclistamab (multiple myeloma) – Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nonacog beta pegol (haemophilia B, children < 12 years) – Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Routine practice data collection for brexucabtagene autoleucel acc. to the Law for More Safety in the Supply of Medicines (GSAV): Evaluation of the study protocol (Version 3.0) and the statistical analysis plan (Version 3.0) – Fourth addendum to Commission]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Migalastat (Fabry disease) – Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sacituzumab govitecan (breast cancer) – Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trifluridine/tipiracil (combination with bevacizumab; colorectal cancer) – Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cipaglucosidase alfa (Pompe disease) – Benefit assessment according to § 35a Social Code Book (SGB) V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin (renal insufficiency) - Benefit assessment according to § 35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Eftrenonacog alfa (haemophilia B) – Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mavacamten (cardiomyopathy) – Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (NSCLC, combination with platinum-based chemotherapy, neoadjuvant) – Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Penile traction therapy for induratio penis plastica]
2023     NIHR Health Technology Assessment programme Implementing early rehabilitation and mobilisation for children in UK paediatric intensive care units: the PERMIT feasibility study
2023     Health Information and Quality Authority (HIQA) Health technology assessment of the addition of spinal muscular atrophy (SMA) to the National Newborn Bloodspot Screening Programme
2023     Health Information and Quality Authority (HIQA) An overview of national approaches to stockpiling of medical countermeasures for public health emergencies
2023     Health Information and Quality Authority (HIQA) Ultra-hypofractionated adjuvant radiotherapy for breast cancer: evidence synthesis to support a generic justification decision
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: urinary tract infection in people aged 14 and over - diagnostic guidelines, optimal use of 1st- and 2nd-line treatments and follow-up ]
2023     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Cost-utility analysis of universal neonatal screening for critical congenital heart disease based on pulsioximetry in Spain]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tisagenlecleucel (diffuse large B-cell lymphoma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V (expiry of the decision)]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Loncastuximab tesirine (DLBCL and HGBL) – Addendum to Commission A23-45]
2023     WorkSafeBC Low intensity pulsed ultrasound (LIPUS) for preventing fractures
2023     WorkSafeBC Efficacy of eye movement desensitization and reprocessing (EMDR) as treatment for major depression
2023     WorkSafeBC Firefighting and polycythemia vera
2023     WorkSafeBC HEPA filters and nanomaterials
2023     WorkSafeBC Hemorrhoids and heavy lifting
2023     WorkSafeBC Association between wearing orthosis and developing metatarsal stress fractures
2023     WorkSafeBC Causal association between firefighting and hypersensitivity pneumonitis
2023     Canary Health Service [Cost-effectiveness of newborn screening for tyrosinemia type I (update)]
2023     NIHR Health Services and Delivery Research programme Remote monitoring for long-term physical health conditions: an evidence and gap map
2023     NIHR Health Services and Delivery Research programme What factors are associated with informal carers’ psychological morbidity during end-of-life home care? A systematic review and thematic synthesis of observational quantitative studies
2023     NIHR Health Technology Assessment programme One versus three weeks hypofractionated whole breast radiotherapy for early breast cancer treatment: the FAST-Forward phase III RCT
2023     Penn Medicine Center for Evidence-based Practice (CEP) Antibiotic-laden bone cement
2023     NIHR Health Technology Assessment programme Pragmatic randomised controlled trial of guided self-help versus individual cognitive behavioural therapy with a trauma focus for post-traumatic stress disorder (RAPID)
2023     NIHR Health Technology Assessment programme Appropriate design and reporting of superiority, equivalence and non-inferiority clinical trials incorporating a benefit–risk assessment: the BRAINS study including expert workshop
2023     Penn Medicine Center for Evidence-based Practice (CEP) Medication review and reconciliation in the outpatient setting
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [At a glance: screening and management algorithm management of precancerous lesions - cervical cancer and population-based screening]
2023     Canary Health Service [Evaluation of the lung cancer screening program]
2023     Canary Health Service [Percutaneous ethanol injection in thyroid nodular pathology and metastatic cervical adenopathies]
2023     Canary Health Service [Effectiveness and safety of bioelectrical stimulation techniques in fibromyalgia: systematic review]
2023     Canary Health Service [Evaluation of patient involvement in health technology assessment]